International Journal of Hematology

, Volume 107, Issue 5, pp 551–558 | Cite as

Outcomes of strategic alternative donor selection or suspending donor search based on Japan Marrow Donor Program coordination status

  • Naomi Kawashima
  • Satoshi Nishiwaki
  • Naoko Shimizu
  • Sonoko Kamoshita
  • Kyoko Watakabe
  • Emi Yokohata
  • Shingo Kurahashi
  • Yukiyasu Ozawa
  • Koichi Miyamura
Original Article
  • 44 Downloads

Abstract

In allogeneic hematopoietic stem cell transplantation (allo-HSCT) from unrelated donors, delays in donor search are adversely associated with patient outcome. However, the optimal duration for either waiting for an unrelated donor or selecting alternative sources remains undetermined. Using data from the Japan Marrow Donor Program (JMDP) registry, we retrospectively analyzed 349 adult patients who had searched for unrelated donors. Two hundred and three patients received allo-HSCT from JMDP donors (Group A) with a median of 140 days required to identify a donor, 60 received allo-HSCT from alternative sources (Group B) after a median of 111.5 days at which point either all donor candidates had failed or the patient achieved a second or subsequent complete remission, and 77 suspended allo-HSCT (Group C) after a median of 310 days. The 5-year overall survival (OS) rate in Group A was superior to that of Group C (48.6 vs 38.5%, P = 0.001). Although Group B included more patients with high or very high disease risk index (DRI) at the time of allo-HSCT compared with Group A, the 5-year OS was not significantly different between Groups A and B (48.6 vs 40.9%, P = 0.07), indicating that switching to alternative donors may benefit patients with high DRI.

Keywords

Bone marrow transplantation Allogeneic hematopoietic stem cell transplantation Unrelated donor JMDP 

Notes

Acknowledgements

We thank the members of the Japan Marrow Donor Program for generously providing donor search information. This work was supported in part by a Grant-in-Aid from the Ministry of Health, Labor, and Welfare, Japan (H26-Nanchi- (Immunology)-Ippan-101 and H28-Nanchi- (Immunology)-Ippan-101).

Compliance with ethical standards

Conflict of interest

The authors declare no competing financial interests.

References

  1. 1.
    Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813–26.CrossRefPubMedGoogle Scholar
  2. 2.
    Karanes C, Nelson GO, Chitphakdithai P, Agura E, Ballen KK, Bolan CD, et al. Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant. 2008;14:8–15.CrossRefPubMedGoogle Scholar
  3. 3.
    Kurosawa S, Yakushijin K, Yamaguchi T, Atsuta Y, Nagamura-Inoue T, Akiyama H, et al. Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia/myelodysplastic syndrome: an analysis of the Japan Transplant Outcome Registry. Bone Marrow Transplant. 2013;48:529–36.CrossRefPubMedGoogle Scholar
  4. 4.
    McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010;28:1878–87.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Guo Z, Gao HY, Zhang TY, Liu XD, Yang K, Lou JX, et al. Analysis of allogeneic hematopoietic stem cell transplantation with high-dose cyclophosphamide-induced immune tolerance for severe aplastic anemia. Int J Hematol. 2016;104:720–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Miyamoto T, Takashima S, Kato K, Takase K, Yoshimoto G, Yoshida S, et al. Comparison of cyclosporine and tacrolimus combined with mycophenolate mofetil in prophylaxis for graft-versus-host disease after reduced-intensity umbilical cord blood transplantation. Int J Hematol. 2017;105:92–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Chevallier P, Labopin M, Milpied N, Bilger K, Socie G, Yakoub-Agha I, et al. Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant. 2014;49:361–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Kanda J, Fuji S, Kato S, Takami A, Tanaka J, Miyamura K, et al. Decision analysis for donor selection in stem cell transplantation-HLA-8/8 allele-matched unrelated donor vs HLA-1 AG mismatched related donor. Blood Cancer J. 2014;4:e263.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kanda J, Ichinohe T, Kato S, Uchida N, Terakura S, Fukuda T, et al. Unrelated cord blood transplantation vs related transplantation with HLA 1-antigen mismatch in the graft-versus-host direction. Leukemia. 2013;27:286–94.CrossRefPubMedGoogle Scholar
  10. 10.
    Terakura S, Atsuta Y, Tsukada N, Kobayashi T, Tanaka M, Kanda J, et al. Comparison of Outcomes of 8/8 and 7/8 Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Cord Blood Transplantation in Adults with Acute Leukemia. Biol Blood Marrow Transplant. 2016;22:330–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Kurosawa S, Yamaguchi T, Miyawaki S, Uchida N, Kanamori H, Usuki K, et al. A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission. Blood. 2011;117:2113–20.CrossRefPubMedGoogle Scholar
  12. 12.
    Koreth J, Pidala J, Perez WS, Deeg HJ, Garcia-Manero G, Malcovati L, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol. 2013;31:2662–70.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Dini G, Valsecchi MG, Micalizzi C, Busca A, Balduzzi A, Arcese W, et al. Impact of marrow unrelated donor search duration on outcome of children with acute lymphoblastic leukemia in second remission. Bone Marrow Transplant. 2003;32:325–31.CrossRefPubMedGoogle Scholar
  14. 14.
    Frassoni F, Labopin M, Powles R, Mary JY, Arcese W, Bacigalupo A, et al. Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 2000;355:1393–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Craddock C, Labopin M, Pillai S, Finke J, Bunjes D, Greinix H, et al. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia. 2011;25:808–13.CrossRefPubMedGoogle Scholar
  16. 16.
    Heemskerk MB, van Walraven SM, Cornelissen JJ, Barge RM, Bredius RG, Egeler RM, et al. How to improve the search for an unrelated haematopoietic stem cell donor. Faster is better than more! Bone Marrow Transplant. 2005;35:645–52.CrossRefPubMedGoogle Scholar
  17. 17.
    Lown RN, Shaw BE. Beating the odds: factors implicated in the speed and availability of unrelated haematopoietic cell donor provision. Bone Marrow Transplant. 2013;48:210–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664–71.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Ustun C, Lazarus HM, Weisdorf D. To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century. Bone Marrow Transplant. 2013;48:1497–505.CrossRefPubMedGoogle Scholar
  20. 20.
    Pohlen M, Groth C, Sauer T, Gorlich D, Mesters R, Schliemann C et al. Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (60 years). Bone Marrow Transplant 2016;51(11):1441–1448.CrossRefPubMedGoogle Scholar
  21. 21.
    Barker JN, Krepski TP, DeFor TE, Davies SM, Wagner JE, Weisdorf DJ. Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow. Biol Blood Marrow Transplant. 2002;8:257–60.CrossRefPubMedGoogle Scholar
  22. 22.
    Pallua S, Giesinger J, Oberguggenberger A, Kemmler G, Nachbaur D, Clausen J, et al. Impact of GvHD on quality of life in long-term survivors of haematopoietic transplantation. Bone Marrow Transplant. 2010;45:1534–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Kurosawa S, Yamaguchi T, Mori T, Kanamori H, Onishi Y, Emi N, et al. Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia. Bone Marrow Transplant. 2015;50:1241–9.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  1. 1.Department of HematologyJapanese Red Cross Nagoya First HospitalNagoyaJapan
  2. 2.Department of Hematology and OncologyNagoya University Graduate School of MedicineNagoyaJapan

Personalised recommendations